From: Mechanisms of HIF-driven immunosuppression in tumour microenvironment
Drug | Target | Mechanism of inhibition | Tumour | Ref. |
---|---|---|---|---|
Acriflavine | HIF-1 | Prevents HIF-1α/HIF-1β dimerization | Prostate and colorectal cancer | |
Anthracyclines | HIF-1 | Inhibits HIF-1 transcriptional activity | Hepatocellular carcinoma, prostate cancer | [92] |
Cardenolides | Breast cancer | [96] | ||
PT2385 | HIF-2 | Disrupts HIF-2α/ARNT heterodimerization and inhibits HIF-2α target gene expression | Clear cell renal cell carcinoma | [93] |
MK-6482 | [94] | |||
Benzopyranyl triazole | HIF-1 | Increases HIF-1α hydroxylation and subsequent HIF-1α protein degradation | Used in combination with EGFR inhibitor gefitinib in lung and breast cancer | [97] |
BIX01294 at low dosage | Hepatocellular carcinoma | [98] | ||
IDF-1174 | HIF-1 | Increases HIF-1α protein degradation | Hepatocellular carcinoma, colorectal carcinoma | [99] |
LBH589 | Diffuse large B-cell lymphoma, Hodgkin lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer and NSCLC | [99] | ||
MPT0G157 | Colorectal cancer | [100] | ||
Vorinostat | HIF-1, HIF-2 | Decreases HIF-1/2α translation/nuclear localization/stability, increases HIF-1/2 degradation | Hepatocellular carcinoma | [99] |
Trastuzumab (Herceptin) | HIF-1 targets | Target oncogenic growth factor signalling pathways regulated by HIF-1 | Breast cancer | [24] |
Imatinib | Gastric gastrointestinal stromal tumours | |||
Galunisertib | HIF-1 targets | TGFβRI kinase inhibitor | Breast, colon, lung cancers, and hepatocellular carcinoma | [24] |
Lenvatinib | HIF-1 targets | VEGF inhibitor | Hepatocellular carcinoma | [101] |
SCH58261 | HIF-1/2 targets | A2AR antagonist; inhibits immunosuppressive adenosine in TME | Head and neck squamous cell carcinoma | [102] |